Loading…
Connect Biopharma Holdings Limited is projected to rise to $3.45 by 2027, a +37% move from its current price of $2.51. CNTB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.39 | $2.51 | $2.64 | +0.07% |
| Jul 13 | $2.34 | $2.51 | $2.70 | +0.14% |
| Jul 14 | $2.31 | $2.52 | $2.74 | +0.21% |
| Jul 15 | $2.28 | $2.52 | $2.78 | +0.29% |
| Jul 16 | $2.25 | $2.52 | $2.82 | +0.36% |
| Jul 17 | $2.23 | $2.52 | $2.85 | +0.43% |
| Jul 18 | $2.21 | $2.52 | $2.88 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.21 | $2.52 | $2.88 | +0.50% |
| Week 2 | $2.10 | $2.54 | $3.05 | +1.00% |
| Week 3 | $2.03 | $2.55 | $3.20 | +1.51% |
| Week 4 | $1.97 | $2.56 | $3.33 | +2.02% |
| Week 5 | $1.92 | $2.57 | $3.46 | +2.53% |
| Week 6 | $1.87 | $2.59 | $3.57 | +3.04% |
| Week 7 | $1.83 | $2.60 | $3.68 | +3.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Connect Biopharma Holdings Limited is a healthcare company operating as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
The company was founded in 2012 and is headquartered in San Diego, California.
CNTB is a healthcare stock with a current price of $2.66 per share. It has a market cap of $167.48M and ranks 3946 overall by market capitalization. The price outlook reflects the provided forecast, showing a near-term baseline at $2.66 in 2026, followed by a rising trajectory in subsequent years, with long-term upside indicated by higher average prices and substantial max estimates.
Forecasts project gradual appreciation beyond 2026, with 2027 average at $3.68 and 2030 average at $3.89. The long-range view shows notable upside, with 2040 average at $13.41 and 2050 average at $28.44, and max values climbing to $28.54 (2040) and $65.41 (2050). Returns (ROI) escalate from 0% in 2026 to as high as 969.2% by 2050, with a bullish tilt developing through the forecast horizon.
A major floor 31.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.7% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 47.0% above — clearing it would confirm fresh momentum.
Key CNTB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNTB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.39 | Buy | $2.44 | Buy |
| MA 10 | $2.38 | Buy | $2.37 | Buy |
| MA 20 | $2.22 | Buy | $2.30 | Buy |
| MA 50 | $2.30 | Buy | $2.34 | Buy |
| MA 100 | $2.53 | Sell | $2.39 | Buy |
| MA 200 | $2.36 | Buy | $2.27 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.97 | Neutral |
| Stoch RSI (14) | 75.23 | Neutral |
| CCI (20) | 120.65 | Buy |
| Williams %R (14) | -22.39 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 20.10 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 77.61 | Neutral |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 59.14 | Neutral |
| Momentum (10) | 0.44 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 2.44 | Buy |
| ADX (14) | 15.38 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is bullish. RSI14 is 60, and sentiment is listed as BULLISH, indicating positive momentum in the near term. Price action sits above both key moving averages, with sma50 at $2.30 and sma200 at $2.36, suggesting underlying strength.
Trading range for the last 30 days spans from $1.91 to $3.70, with near-term support at $1.99 and resistance at $2.66. The configuration implies a potential breakout if the price clears the $2.66 resistance on renewed buying pressure.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.99 | $2.51 | $3.68 | 0% | Neutral | |
| $2.54 | $3.45 | $5.07 | +37% | Bullish | |
| $2.23 | $3.22 | $5.02 | +28% | Bullish | |
| $2.37 | $3.58 | $5.85 | +43% | Bullish | |
| $2.25 | $3.54 | $6.01 | +41% | Bullish | |
| $2.47 | $4.04 | $7.09 | +61% | Bullish | |
| $3.63 | $6.18 | $11.17 | +146% | Bullish | |
| $3.58 | $6.31 | $11.71 | +152% | Bullish | |
| $3.51 | $6.42 | $12.20 | +156% | Bullish | |
| $3.76 | $7.13 | $13.84 | +184% | Bullish | |
| $5.21 | $11.59 | $24.64 | +362% | Bullish | |
| $10.71 | $23.79 | $54.73 | +848% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.99 | $2.51 | $3.02 | +0.00% |
| August 2026 | $2.12 | $2.56 | $3.22 | +2.16% |
| September 2026 | $2.19 | $2.68 | $3.43 | +4.46% |
| October 2026 | $2.11 | $2.61 | $3.39 | -2.61% |
| November 2026 | $2.06 | $2.58 | $3.40 | -1.14% |
| December 2026 | $2.19 | $2.76 | $3.68 | +6.91% |
Click any year to see its month-by-month CNTB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CNTB price prediction for 2026 points to an average of $2.51 (low $1.99, high $3.68) — a potential gain of 0% on today's $2.51. Price action looks broadly range-bound.
In 2027, CNTB is projected to trade between $2.54 and $5.07, averaging $3.45 — a potential gain of +37% from today's $2.51. That is up +37% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Connect Biopharma Holdings Limited's 2028 outlook centres on $3.22, within a $2.23 to $5.02 range. That is -7% versus the projected 2027 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2029, CNTB could reach as high as $5.85, with a base case around $3.58 and support toward $2.37 — roughly +43% from $2.51. Buyers look set to stay in control over this stretch.
Expect CNTB to range from $2.25 to $6.01 through 2030. The $3.54 average target implies a +41% move from current prices. That is -1% versus the projected 2029 average. Momentum favours further upside here.
The CNTB price prediction for 2031 points to an average of $4.04 (low $2.47, high $7.09) — a potential gain of +61% on today's $2.51. Buyers look set to stay in control over this stretch.
In 2032, CNTB is projected to trade between $3.63 and $11.17, averaging $6.18 — a potential gain of +146% from today's $2.51. That is up +53% on the projected 2031 average. Momentum favours further upside here.
Connect Biopharma Holdings Limited's 2033 outlook centres on $6.31, within a $3.58 to $11.71 range. That is up +2% on the projected 2032 average. That marks a +152% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CNTB could reach as high as $12.20, with a base case around $6.42 and support toward $3.51 — roughly +156% from $2.51. Momentum favours further upside here.
Expect CNTB to range from $3.76 to $13.84 through 2035. The $7.13 average target implies a +184% move from current prices. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CNTB price prediction for 2040 points to an average of $11.59 (low $5.21, high $24.64) — a potential gain of +362% on today's $2.51. Momentum favours further upside here.
In 2050, CNTB is projected to trade between $10.71 and $54.73, averaging $23.79 — a potential gain of +848% from today's $2.51. That is up +105% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CNTB today (≈ 398.406375 CNTB) could be worth
$9,479.48
+$8,479.48 (+848%) by 2050 · US Dollar
Based on the average projected CNTB price of $23.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNTBwould be worth at today's price.
$1,000 invested in CNTB on Jul 10, 2025 (≈ 869.565235 CNTB) would be worth
$2,182.61
+$1,182.61 (+118.3%) today · 2.18× · US Dollar
Based on a CNTB entry price of $1.15 vs. today's $2.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.46 | $1,020.33 | +2.0% |
| 1 month ago | $2.08 | $1,206.73 | +20.7% |
| 3 months ago | $2.82 | $890.07 | -11.0% |
| 6 months ago | $2.12 | $1,183.96 | +18.4% |
| 1 year ago | $1.15 | $2,182.61 | +118.3% |
| All time (5.0y) ago | $21.74 | $115.46 | -88.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNTB forecast.
Our base-case forecast reaches $5.00 around 2032.
Implied market cap at $5.00: $314.82M
The multi-year forecast shows a path of rising averages and increasing upside. For 2026, the min is $1.99, the avg is $2.66, and the max is $3.92, with a 0% ROI and a neutral sentiment. From 2027 onward, the outlook improves: 2027 avg $3.68 with a 38.3% ROI and bullish sentiment; 2028 avg $3.46 (30% ROI); 2029 avg $3.90 (46.5% ROI); 2030 avg $3.89 (46.3% ROI).
Looking further, 2031 shows avg $4.54 (70.7% ROI), 2032 avg $6.97 (162.1% ROI), 2033 avg $7.09 (166.6% ROI), 2034 avg $7.25 (172.7% ROI), and 2035 avg $8.11 (204.7% ROI), all with bullish sentiment. The horizon extends to 2040 with avg $13.41 (404.3% ROI) and to 2050 with avg $28.44 (969.2% ROI), both still labeled bullish. These figures are estimates and not guarantees, reflecting upside potential amid ongoing uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.89, with a min of $2.47 and a max of $6.61; the expected ROI is 46.3% and the sentiment is BULLISH.
Forecasts show a shift to bullish sentiment from 2027 onward, with multi-year upside reflected by an average approaching $28.44 by 2050 and a potential ROI of up to 969.2%, though 2026 is neutral and outcomes are not guaranteed.
Yes. The forecast lists a 2027 max of $5.41, a 2029 max of $6.37, and a 2030 max of $6.61, indicating potential to exceed $5 in coming years.
For 2040, the min is $6.04, the avg is $13.41, and the max is $28.54, with a 404.3% ROI and bullish sentiment.
For 2050, the min is $12.80, the avg is $28.44, and the max is $65.41, with a 969.2% ROI and bullish sentiment.
Connect Biopharma Holdings Limited Community Discussion
0Share your Connect Biopharma Holdings Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.